Similar Items: Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma
- The Incidence of Hepatocellular Carcinoma after Balloon-Occluded Retrograde Transvenous Obliteration
- Severe Thrombocytopenia Is Associated With Bleeding in Hepatocellular Carcinoma Patients Receiving Antiangiogenic Therapy
- Adverse event severity in weekend and after-hours interventional radiology: a multi-institutional quality review
- Impairments in signaling cascades mediating the progression of liver disease from chronic hepatitis to hepatocellular carcinoma in animal and human models
- Risk factors and critical thresholds for glucocorticoid-induced ocular adverse reactions in children: implications for muscle and neuromuscular disease management
- Blood pressure telemonitoring and the incidence of cardiovascular events: a records based, matched patient analysis